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Background: The mechanism by which low-dose aspirin prevents atherosclerotic heart disease is not fully understood. In this study, we examined 
the role of aspirin in protecting endothelial cell (EC) survival against oxidized LDL (oxLDL).
Methods: DNA synthesis (by 3H-thymidine incorporation), cell viability (by MTT assay), and expression of the prosurvival fibroblast growth factor 
2 (FGF2) were evaluated in cultured human coronary artery ECs (HCAECs) treated with copper oxLDL and/or aspirin. FGF2-luciferase reporter gene 
system containing serial deletions of the FGF2 5’-flanking regions were constructed and examined for FGF2 promoter activities after transient 
transfection into EC. DNA methylation of CpG dinucleotides was performed using bisulfite genomic DNA sequencing.
Results: OxLDL inhibited FGF2 expression and DNA synthesis in a time- and dose-dependent manner; supplementation with FGF2 significantly 
attenuated the negative effects of oxLDL on EC proliferation. In contrast, aspirin alone had a biphasic effect on ECs, modestly increasing FGF2 at 
concentrations ≤ 0.2 mmol/l (i.e., a low, physiologically relevant dose) but decreasing FGF2 at concentrations > 0.2 mmol/l. Coincubation of cells 
with 0.2 mmol/l aspirin and 100 μg/ml oxLDL significantly attenuated the effects of oxLDL. To confirm that FGF2 regulation is an important pathway 
in aspirin-mediated improvement of EC survival, we investigated the effects of aspirin on oxLDL-induced transcriptional activity of FGF2 promoter. 
We have found that 0.2 mmol/l but not 5 mmol/l aspirin prevented oxLDL-induced transcriptional repression of the FGF2 promoter, which was 
mediated through the Akt signaling pathway and involved demethylation of CpG dinucleoyides.
Conclusions: Low-dose aspirin provides cytoprotection against oxLDL by maintaining intracellular FGF2 transcription, which is required for 
EC survival. This novel effect of aspirin is independent of its antiplatelet activity and may account for its long-term benefits in patients with 
atherosclerotic cardiovascular disease.
